Biblio

Author Title [ Type

] Year

Filters: Author is Thépot, Sylvain [Clear All Filters]

Journal Article

Lefeuvre C, Thépot S, Mercier-Delarue S, Bouille T, Michonneau D, Le Goff J, Salmona M. Adenovirus F41 infection and liver cytolysis in adult hematopoietic stem cell transplant recipients. J Med Virol. 2023;95(7):e28922.

Peterlin P, Le Bris Y, Turlure P, Chevallier P, Ménard A, Gourin M-P, Dumas P-Y, Thépot S, Berceanu A, Park S, et al. CPX-351 in higher risk myelodysplastic syndrome and chronic myelomonocytic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Haematol. 2023.

Itzykson R, Santini V, Thépot S, Ades L, Chaffaut C, Giagounidis A, Morabito M, Droin N, Lübbert M, Sapena R, et al. Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network. J Clin Oncol. 2022:JCO2200437.

Orvain C, Beloncle F, Hamel J-F, Thépot S, Mercier M, Kouatchet A, Farhi J, François S, Guardiola P, Asfar P, et al. Different Impact of the Number of Organ Failures and Graft-Versus-Host Disease on the Outcome of Allogeneic Stem Cell Transplantation Recipients Requiring Intensive Care. Transplantation. 2016.

Jullien M, Orvain C, Berceanu A, Couturier M-A, Guillaume T, Peterlin P, Garnier A, Le Bourgeois A, Klemencie M, Schmidt A, et al. Early Post-Transplant Serum Ferritin Levels Predict Survivals in Recipients of Haploidentical Stem Cell Transplantation Using PTCY as GVHD Prophylaxis. Transplant Cell Ther. 2021.

Jullien M, Orvain C, Berceanu A, Couturier M-A, Guillaume T, Peterlin P, Garnier A, Le Bourgeois A, Klemencie M, Schmidt A, et al. Impact of allogeneic stem cell transplantation comorbidity indexes after haplotransplant using post-transplant cyclophosphamide. Cancer Med. 2021.

Guillaume T, Thépot S, Peterlin P, Ceballos P, Le Bourgeois A, Garnier A, Orvain C, Giltat A, François S, Le Bris Y, et al. Prophylactic or preemptive low-dose azacitidine and donor lymphocyte infusion to prevent disease relapse following allogeneic transplantation in patients with high risk acute myeloid leukemia or myelodysplastic syndrome. Transplant Cell Ther. 2021.

Lacombe V, Gomes CNunes, Robin J-B, Thépot S, François S, Cottin L, Ugo V, Dieu X, Abgueguen P, Daniel V, et al. Risk of infection according to the gamma globulin level in the 100 days following allogeneic stem cell transplantations. Eur J Haematol. 2021.